BUSINESS
ECB, Fed poised to confront 'stagflation' -- What's the impact for investors?
In India, stagflationary trends due to the supply shock will unfold in the coming months. Persistent inflation would also lead to demand destruction and downtrading.
BUSINESS
Insecticides (India): A value bet on normal monsoon
IIL's export share can also improve to the 15-20 percent range of revenue, owing to higher penetration in new geographies, and a pick-up in product registration
BUSINESS
This value pick has a favourable demand-supply dynamics, post Russian sanctions
Shortage of graphite electrodes is likely in the global markets, which puts the spotlight on HEG
BUSINESS
Ukraine stalemate: Is Volcker moment coming for Fed and investors?
De-globalization theme is firmly on display
BUSINESS
Ukraine War: What sums up India’s stand on Russia at UN?
Bilateral trade between the two countries may be modest, but deep military cooperation is the binding force between India and Russia
BUSINESS
Galaxy Surfactants: Navigating supply-chain turmoil with poise
Galaxy Surfactants is positive of achieving a 6-8 percent volume growth in the next fiscal
BUSINESS
Hikal: Green integrity in the spotlight, more than financials
We are entering increasing interest rate scenario. Liquidity is drying which simply means institutional fund flows would be much more selective and sensitive to quality aspect
BUSINESS
What does interest rate hike cycle by US Fed mean for metal stocks?
Investors in metals need to keep a close watch on Chinese policy, post Olympics
BUSINESS
IPCA Labs: Does return of pre-COVID expenses derail investment case?
Ipca lab's key challenge with respect to APIs is on the mend.
BUSINESS
Divi’s Labs: Investment to improve yields provides the edge
Operating margins of Divi's are likely to remain elevated, given the benefits from the recent investments on improving yields and backward integration
BUSINESS
Will the Street reward Aurobindo Pharma’s bet on domestic formulations?
The Aurobindo Pharma stock currently trades at a valuation of 6.6x FY23e EV/EBITDA, which is at a substantial discount to its Indian peers with an exposure in the US market
BUSINESS
Inflation scare: Is early Fed rate hike in the offing before March meet?
Fed Funds futures are pricing in about five rate hikes of 25 basis points each in 2022 and a few FOMC members are getting vocal about the need for a 50 bps rate hike in the 15-16th March meet, to start with
BUSINESS
Suven Pharma: Steady cash flow conversion opportunity merits attention
Suven Pharma remains conservative in its outlook and provides visibility for the next six months. It is confident of executing Q3 sales run rate for the next two quarters
BUSINESS
Early signs of normal monsoon and what it means for Indian stock market...
Initial weather forecasts suggest India would have a normal monsoon this year. This would lead to strong performance in rural related sectors such as FMCG, agrochemicals, tractors and two wheelers
BUSINESS
Clean Science and Technology: Green chemistry, process innovation key levers
Over the years, Clean Science and Technology has optimised the use of conventional raw materials, improved yields, and reduced effluent discharges, which have consequently helped in cost competitiveness
BUSINESS
Ami Organics: Forte in niche chemistry for speciality pharma molecules
One of the key strengths of Ami Organics, in our opinion, is its expertise in Piperazine chemistry
BUSINESS
Lupin: A long gestation period ahead
From a big product launch perspective, FY24 onwards is a more reasonable time period to watch for Lupin
BUSINESS
Cadila: Biosimilars, oncology portfolio hold promise for medium term
The Moraiya plant’s pending USFDA approval is crucial for Cadila’s US ambition
BUSINESS
Navin Fluorine: How good is the investment case with rising competition?
Navin Fluorine has proven credentials in the multi-step chemistry of fluorochemicals, which is getting stronger with R&D focus
BUSINESS
For chemicals, Budget 2022 is a minor reversal of import substitution policy
A reduction of duties on key chemicals to help soften raw material inflation
BUSINESS
Sun Pharma: Traction in specialty impressive
Overall, traction for specialty products for Sun Pharma got a helping hand from the leading products Ilumya, Cequa, Levulan and Absorica
BUSINESS
Laurus Labs: Diversification away from ARVs on track
The share of the Laurus antiretroviral business in total is expected to be less than 1/3rd by 2025, compared to 50 percent now as the company’s other engines of growth gain traction
BUSINESS
Dr Reddy’s: Supported by traction in limited competition products
Sales growth in North America was helped by healthy market share for the generic version of Vascepa
BUSINESS
Fed stance heightens risks for emerging markets
Pace at which US Fed intends to roll back accommodative monetary policy can unnerve markets. While upbeat wage growth signifies robust demand conditions leading to better earnings prospects, there is a high risk for valuation contraction due to lower liquidity
